The kit allows scientists to use mRNA-lipid nanoparticles to generate high yields of engineered primary human T cells in a simple workflow. The GenVoy-ILM T-cell kit uses lipid nanoparticles designed to exploit endogenous uptake pathways to deliver mRNA into activated human primary T cells to mediate titratable, uniform expression levels with high cell viability, according to the company.

The mRNA-lipid nanoparticles are compatible with established T-cell culture media, allowing for rapid integration into existing workflows. The kit can be used for the development of T-cell therapies.

Unchained Labs adds automated gene therapy, vaccine applications
Unchained Labs has rolled out new gene therapy and vaccine applications on its Big Tuna automated buffer exchange platform for biologics. The system can...

DIANT licenses continuous manufacturing tech
The University of Connecticut has licensed its continuous manufacturing technology for pharmaceutical nanoparticles to DIANT Pharma.